Bystritsky A, Waikar S V
Neuropsychiatric Institute, University of California, Los Angeles.
J Nerv Ment Dis. 1994 Sep;182(9):485-7. doi: 10.1097/00005053-199409000-00001.
Patient blindability was examined in clinical, psychopharmacological, double-blind, placebo-controlled trials involving medications for obsessive-compulsive disorder and major depression. Based on the presence of clinical improvement and side effects, patients were able to determine correctly whether they took medication versus placebo. On the basis of these preliminary findings, the authors question the blindability of patients in clinical trials. Implications for the continued use of double-blind, placebo-controlled trials are discussed.
在涉及强迫症和重度抑郁症药物的临床、精神药理学、双盲、安慰剂对照试验中,对患者的盲法可行性进行了研究。根据临床改善情况和副作用的出现,患者能够正确判断自己服用的是药物还是安慰剂。基于这些初步研究结果,作者对临床试验中患者的盲法可行性提出质疑。文中还讨论了对继续使用双盲、安慰剂对照试验的影响。